Institution · Isarna Therapeutics (Germany)

Most cited papers from Isarna Therapeutics (Germany)

Isarna Therapeutics (Germany)

What are the most cited papers from Isarna Therapeutics (Germany)?

The most cited paper from Isarna Therapeutics (Germany) is "First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery" (Norbert Pfeiffer, Bogomil Voykov, Giulia Renieri et al., 2017), with 69 citations. Next come "TGF-β1 and TGF-β2 abundance in liver diseases of mice and men" (62) and "Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma" (60).

Published TypeFieldAccess

Showing 22 of 22 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery Norbert Pfeiffer, Bogomil Voykov, Giulia Renieri et al. · PLoS ONE Open access	30 Nov 2017	69
2	TGF-β1 and TGF-β2 abundance in liver diseases of mice and men Anne Dropmann, Tatjana Dediulia, Katja Breitkopf‐Heinlein et al. · Oncotarget Open access	21 Jan 2016	62
3	Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma Katharina Seystahl, Alexandros Papachristodoulou, Isabel Burghardt et al. · Molecular Cancer Therapeutics Open access	4 Apr 2017	60
4	Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas Alexandros Papachristodoulou, Manuela Silginer, Michael Weller et al. · Clinical Cancer Research Open access	17 Sep 2019	51
5	TGF-β2 silencing to target biliary-derived liver diseases Anne Dropmann et al. · Gut Open access	28 Jan 2020	43
6	An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages Isabel Huber‐Ruano, C. Raventós, Isabel Cuartas et al. · Annals of Oncology Open access	21 Jul 2017	30
7	Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors Frank Jaschinski, Hanna Korhonen, Michel Janicot · Methods in molecular biology Book chapter	2015	15
8	Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models Shu-Hung Wang et al. · Frontiers in Immunology Open access	17 Mar 2025	13
9	TGF-β isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity Markus J. Riemenschneider, Maria Hirblinger, Arabel Vollmann‐Zwerenz et al. · Oncotarget Open access	22 Sep 2015	11
10	Potent and selective antisense oligonucleotides targeting the transforming growth factor beta (TGF-β) isoforms in advanced glaucoma: a preclinical evaluation Kathy Hasenbach, Tine Van Bergen, Evelien Vandewalle et al. · Modeling and Artificial Intelligence in Ophthalmology Open access	15 Dec 2016	7
11	A Hyperbolic Discrete Diffusion 3D RNA Inverse Folding Model for Functional RNA Design Dongyue Hou, Shuai Zhang, Mengyao Ma et al. · Journal of Chemical Information and Modeling	12 Jun 2025	5
12	Main results of the First-In Human single ascending dose phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2) in glaucoma filtration surgery Bogomil Voykov, Hagen Thieme, Katharina Cornelia Bell et al. · Investigative Ophthalmology & Visual Science Open access	23 Jun 2017	3
13	Targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA with ISTH0036 as Novel Therapeutic Intervention in Neovascular Ocular Disease Katja Wosikowski, Inge van Hoven, Jooseppi Puranen et al. · Lirias (KU Leuven) Open access	May 2017	1
14	Long-term safety and efficacy of ISTH0036 – a selective TGF-β2 blocking antisense oligonucleotide in preclinical and Phase 1 clinical studies. René Rückert, Marion Ronit Munk, Katja Wosikowski et al. · Investigative Ophthalmology & Visual Science Open access	21 Jun 2021	0
15	TGF-beta 2 als therapeutische Zielstruktur bei cholestatischer Leberfibrose Anne Dropmann, Steven Dooley, Bedair Dewidar et al. · Zeitschrift für Gastroenterologie Conference paper	13 Aug 2019	0
16	Extended preclinical ocular biodistribution and pharmacodynamic profile of ISTH0036, an antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of ophthalmic diseases Katja Wosikowski, Birgit Korbmacher, Monika Krampert et al. · Investigative Ophthalmology & Visual Science Open access	13 Jul 2018	0
17	A phase I First-In Human single ascending dose study of ISTH0036, a potent and selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of primary open-angle glaucoma Bogomil Voykov, Katrin Lorenz, Claudia Schuart et al. · Investigative Ophthalmology & Visual Science Open access	26 Sep 2016	0
18	Anti-fibrotic and anti-inflammatory consequences of TGF-β2 silencing in biliary liver disease Anne Dropmann, Bedair Dewidar, Tatjana Dediulia et al. · Zeitschrift für Gastroenterologie	19 Dec 2016	0
19	Targeting TGF-β2 in chronic liver diseases Anne Dropmann, Hanna Korhonen, Frank Jaschinski et al. · Zeitschrift für Gastroenterologie	16 Jan 2015	0
20	TGF-β2 in Chronic Liver Disease (CLD) and Hepatocellular Carcinoma (HCC) Anne Dropmann, Albrecht Piiper, E M Alonso et al. · Zeitschrift für Gastroenterologie	13 Jan 2014	0
21	Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform with ISTH0036 - a Potent and Selective Antisense Oligonucleotide - for the Treatment of Glaucoma Kathy Hasenbach, Leonie Herrnberger, Sabrina Kuespert et al. · Investigative Ophthalmology & Visual Science	11 Jun 2015	0
22	Efficacy of ISTH0036, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform, in Different Ocular Disease Preclinical Models Michel Janicot, Kathy Hasenbach, Tine Van Bergen et al. · Investigative Ophthalmology & Visual Science	11 Jun 2015	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.